Moreover, in the stratification analysis of the medication, RA patients receiving the CHP in combination with WM treatment showed a trend of reduced risk of IS compared with those receiving WM only, with the exception of RA patients taking TNF-antagonist (Table 2). Here, TNF is linked to rheumatoid arthritis.